Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2014 Press Release: Cancer Medicine Becoming Ever More Precise, Practice-Changing Results at ESMO 2014 Show

30 Sep 2014

Lugano/Madrid, 30 September 2014 – A record number of 19,859 attendees at the ESMO 2014 Congress discussed changes to oncology that will soon have a positive impact on the care of patients around the world.

“We are particularly pleased to see participants from 131 countries at the congress this year,” said ESMO President Rolf Stahel. “Although this is the congress of the European Society for Medical Oncology, it is truly a global congress with growing participation from countries outside Europe, especially the far east.”

A theme of the congress was “precision medicine in cancer care”, said Professor Johann de Bono, from Royal Marsden Hospital and the Insititute of Cancer Research, UK, and Chair of the ESMO 2014 Scientific Committee. “We are increasingly able to target cancer treatments to the important molecular mechanisms that underpin the malignancy. This is what we mean by precision medicine.”

Scientific highlights of ESMO 2014 included trials that will change clinical practice very soon, noted de Bono. “We were excited to hear the results of a number of very important studies that will have a direct impact on the way we treat patients in the clinic, in a range of tumour types including lung cancer, breast cancer, and melanoma,” de Bono said. “An improvement in treatment for cancer anorexia and cachexia, as reported at this congress, is also a much-needed advance.”

ESMO has an important role to play in driving further improvements in diagnosis, treatment and care of patients by supporting scientific research, said Stahel. New initiatives include the development of courses on clinical trials to help oncologists who wish to take part in research, and the development of the ESMO Magnitude of Clinical Benefit Scale, which will provide a means of assessing approved therapies by using a number of important clinical measures.

As part of this goal of facilitating research, ESMO will also continue to strengthen its collaborations and connections with other disciplines that are important in developing new therapies, he said. 

“Through these and other initiatives, I am committed to ensuring ESMO uses its power and strength to promote and facilitate clinical and translational research in Europe and ultimately to help improve outcomes for our patients,” said Stahel.


Last update: 30 Sep 2014

About the European Society for Medical Oncology

The European Society for Medical Oncology (ESMO) is the leading European professional organisation committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.

ESMO’s mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice.

The ESMO international community counts more than 9,000 oncology professionals sharing best practices and the latest know-how in cancer treatment and care.

ESMO’s scientific journal, Annals of Oncology, ranks among the top 10 clinical oncology journals worldwide.

To find out more about ESMO, please visit: www.esmo.org

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings